Kiniksa Pharmaceuticals, Ltd. Announces Launch of ARCALYST Named Patient Program
August 16, 2021 at 01:00 pm
Share
Kiniksa Pharmaceuticals, Ltd. announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1a) and interleukin-1 beta (IL-1ß) signaling. The Named Patient Program for ARCALYST was launched in partnership with the specialist services company, WEP Clinical. The program is designed to ensure that physicians outside the U.S. can request ARCALYST on behalf of individual patients who have recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), or deficiency of IL-1 receptor antagonist (DIRA) but reside in countries where ARCALYST is not currently commercially available.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).